The JRKL Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal cell population derived from the HT29 human colorectal adenocarcinoma cell line. This polyclonal knockout pool contains a heterogeneous mixture of cells with diverse indel mutations at the JRKL locus, collectively resulting in loss of JRKL protein function. The product provides a ready-to-use loss-of-function model for investigating JRKL in colorectal cancer without in-house editing.
The parental HT29 cell line, originally isolated from a 44-year-old female with colorectal adenocarcinoma, is a well-characterized epithelial model used in cancer research and toxicology. HT29 cells can undergo enterocytic differentiation and mucin production under specific conditions, making them valuable for intestinal epithelial studies. Their widespread adoption includes investigations of signal transduction, drug response, and oncogenic mechanisms, particularly in colorectal carcinogenesis. The robust genetic and phenotypic features of HT29 provide a reliable platform for knockout-based functional analyses.
JRKL encodes a DNA-binding protein with a helix-turn-helix domain, suggesting a role as a transcriptional regulator. It is implicated in controlling cell proliferation and apoptosis, functioning downstream of the canonical Wnt/??-catenin pathway. Upon Wnt ligand binding to Frizzled receptors, ??-catenin accumulates and partners with TCF/LEF transcription factors to drive target gene expression; JRKL is predicted to be among these targets and may modulate downstream effectors such as BCL2 family apoptosis regulators and cyclins governing cell cycle progression. Through direct DNA binding and interactions with transcriptional co-regulators, JRKL likely fine-tunes gene expression networks governing survival and division. Disruption of JRKL via CRISPR/Cas9 is expected to perturb these networks, offering a system to dissect its contributions to Wnt-driven oncogenesis.
In the HT29 colorectal adenocarcinoma context, JRKL knockout provides a physiologically relevant model to study how loss of this transcriptional regulator influences tumor cell behavior. The polyclonal nature allows examination of population-level responses, reflecting the heterogeneity of solid tumors. Researchers can assess the impact of JRKL disruption on HT29 cell proliferation, apoptosis, cell cycle distribution, and migration??processes frequently deregulated in colorectal cancer. By comparing knockout and wild-type HT29 cells, investigators can delineate JRKL-dependent signaling nodes and evaluate its potential as a therapeutic vulnerability.
Typical applications include functional genomics screens to identify JRKL interaction partners, validation of JRKL as a drug target in colorectal cancer, and elucidation of its role in Wnt pathway regulation. The polyclonal cells are compatible with a broad array of assays: Western blotting and RT-qPCR confirm gene disruption and expression changes; Sanger sequencing with TIDE analysis quantifies editing efficiency; MTT and colony formation assays measure proliferation; Annexin V/PI staining and flow cytometry assess apoptosis and cell cycle; transwell migration assays evaluate motility; and RNA-seq provides transcriptome-wide insights. This versatile tool supports both hypothesis-driven and discovery-based research. For additional technical information, please contact Ascent Research.
